Can B Corp. (CANB) Stock Analysis
DELISTED 2025
What happened to Can B Corp. (CANB) stock?
Can B Corp. (CANB) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Can B Corp. (CANB) trades at $0.01917. Can B Corp. specializes in the development and sale of cannabidiol (CBD) products, focusing on health and wellness. The company operates primarily in the U. Market cap: $1.49M, Sector: Healthcare.
Last analyzed: Jun 14, 2026Analyst Coverage for CANB: CANB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CANB against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
CANB: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Can B Corp. (CANB) Healthcare & Pipeline Overview
Can B Corp. is a U.S.-based company focused on the development and manufacturing of a diverse range of CBD products, including oils, topical creams, and lifestyle items, capitalizing on the growing health and wellness market.
What Is the Investment Thesis for CANB?
Can B Corp. is positioned to capitalize on the expanding CBD market, which is projected to grow significantly as consumer awareness and acceptance of CBD products increase. The company’s diverse product lineup, which includes oils, creams, and lifestyle items, allows it to target various consumer segments seeking health and wellness solutions. Key value drivers include its established brand presence and distribution channels, which enhance market penetration. However, the company faces risks associated with operating in the OTC market, including liquidity challenges and regulatory scrutiny. Investors should monitor Can B Corp.'s ability to scale operations and achieve profitability in a competitive landscape, particularly as consumer demand for CBD products continues to rise.
Based on FMP financials and quantitative analysis
CANB Key Highlights
Market Cap: $0.00B, indicating a very small company size and potential volatility.
- Beta: 0.85, suggesting lower volatility compared to the broader market.
- No dividend yield, reflecting a focus on reinvestment rather than shareholder returns.
- Employee count of 12, highlighting the company's small operational scale.
- Diverse product offerings including oils, topical creams, and lifestyle products, positioning the company well within the health and wellness sector.
Who Are CANB's Competitors?
CANB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CURLF Curaleaf Holdings, Inc. | $9.60 | -2.34% | $2.54B | 53 |
| APHA APHA | $15.27 | -1.04% | 56 | |
| TLRY Tilray Brands, Inc. | $4.67 | -3.31% | $522M | 47 |
| HEXO HEXO Corp. | $0.71 | +2.45% | $31.2M | 50 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CANB's Key Strengths?
Diverse product offerings catering to various consumer segments.
- Established brand names that enhance market recognition.
- Strong focus on health and wellness trends driving consumer interest.
- Ability to adapt to regulatory changes in the CBD market.
What Are CANB's Weaknesses?
Small employee base leading to limited operational capacity.
- Trading on the OTC market may limit visibility and investor confidence.
- Lack of dividend payments may deter income-focused investors.
- Potential challenges in scaling operations to meet growing demand.
What Could Drive CANB Stock Higher?
Potential expansion of product lines targeting new consumer segments.
- Continued growth in consumer interest in CBD products driving sales.
- Strategic partnerships with medical professionals enhancing distribution.
- Exploration of international markets for product distribution.
- Adaptation to regulatory changes in the CBD industry.
What Are the Key Risks for CANB?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainties that could impact product availability.
- Intense competition from both established and emerging CBD companies.
- Market volatility associated with trading on the OTC market.
- Changing consumer preferences that may affect product demand.
What Are the Growth Opportunities for CANB?
- Expansion of Product Lines: Can B Corp. has the opportunity to expand its product offerings within the CBD sector, targeting niche markets such as pet care and beauty products.
- Increased Online Sales: With the rise of e-commerce, Can B Corp. can enhance its online sales strategy to reach a broader audience. The online health and wellness market is expected to grow significantly, driven by consumer preferences for convenience and accessibility. By optimizing its digital marketing efforts and expanding its online presence, Can B Corp. could capture a larger share of this growing market.
- Strategic Partnerships: Forming partnerships with healthcare professionals and wellness influencers can enhance Can B Corp.'s credibility and market reach. Collaborating with professionals in the health sector can facilitate product endorsements and increase consumer trust, potentially leading to higher sales and brand loyalty.
- Geographic Expansion: Can B Corp. can explore opportunities to expand its distribution network beyond the U.S. market. International markets, particularly in Europe and Asia, are increasingly receptive to CBD products, and establishing a presence in these regions could significantly boost the company's revenue potential.
- Regulatory Advancements: As regulations surrounding CBD products continue to evolve, Can B Corp. could benefit from favorable legislative changes that promote the use of CBD in various applications. Keeping abreast of regulatory developments and adapting its product offerings accordingly can position the company to capitalize on new market opportunities.
What Are CANB's Competitive Advantages?
- Established brand presence with multiple product lines catering to diverse consumer needs.
- Strong relationships with healthcare professionals enhancing credibility.
- Diverse distribution channels, including e-commerce and vending machines, increasing accessibility.
- Focus on product quality and compliance with evolving regulations.
- Ability to adapt quickly to market trends and consumer preferences.
What Does CANB Do?
Founded in 2005, Can B Corp. has established itself as a key player in the cannabidiol (CBD) market, specializing in the development, manufacturing, and sale of CBD-derived products. Originally named Canbiola Inc., the company rebranded to Can B Corp. in February 2020 to better reflect its broad range of offerings and commitment to health and wellness. Headquartered in Hicksville, New York, Can B Corp. operates primarily within the United States, providing an extensive selection of hemp-based CBD products that includes oils, topical creams, moisturizers, isolates, gel capsules, spa items, and concentrates. The company markets its products under several brand names, including Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil, catering to a diverse customer base. Can B Corp. sells its products through multiple channels, including its official website, automated vending machines, and partnerships with medical professionals, enhancing its market reach. With a relatively small workforce of 12 employees, Can B Corp. continues to navigate the competitive landscape of the CBD industry, which is characterized by increasing consumer interest in health and wellness products. As the market evolves, Can B Corp. aims to leverage its brand portfolio and product diversity to capture a larger share of the growing CBD market.
What Products and Services Does CANB Offer?
- Develop and manufacture a wide range of CBD products.
- Offer oils, topical creams, moisturizers, isolates, and gel capsules.
- Market products under various brand names including Canbiola and Nu Wellness.
- Sell products through an official website and automated vending machines.
- Collaborate with medical professionals for product distribution.
- Focus on health and wellness market trends to inform product development.
How Does CANB Make Money?
- Generate revenue through the sale of CBD products directly to consumers.
- Utilize multiple sales channels, including e-commerce and physical vending machines.
- Leverage partnerships with healthcare professionals to enhance product distribution.
- Focus on brand differentiation to capture diverse consumer segments.
- Adapt product offerings based on market demand and regulatory changes.
What Industry Does CANB Operate In?
The CBD market is experiencing rapid growth, driven by increasing consumer interest in health and wellness products. The global CBD market size was valued at approximately $2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of around 21% from 2021 to 2028. Can B Corp. operates in a competitive landscape that includes both established pharmaceutical companies and emerging startups focused on CBD products. As regulations evolve, companies like Can B Corp. must adapt to maintain compliance while capitalizing on market opportunities.
Who Are CANB's Key Customers?
- Health-conscious consumers seeking natural wellness solutions.
- Individuals interested in alternative therapies and supplements.
- Medical professionals looking to provide CBD products to patients.
- Retail partners interested in stocking CBD products.
- Consumers purchasing lifestyle products that incorporate CBD.
Company Profile
Can B Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hicksville, US. The company is led by CEO Marco Alfonsi. CANB has traded publicly since 2012.
How Can B Corp. Is Valued
Can B Corp. carries a market capitalization of $1.49M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Can B Corp. stands at 37.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -28.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Can B Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CANB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Diverse product offerings catering to various consumer segments.
- Established brand names that enhance market recognition.
- Strong focus on health and wellness trends driving consumer interest.
- Ability to adapt to regulatory changes in the CBD market.
Bear Case
- Small employee base leading to limited operational capacity.
- Trading on the OTC market may limit visibility and investor confidence.
- Lack of dividend payments may deter income-focused investors.
- Potential challenges in scaling operations to meet growing demand.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CANB Latest News
No recent news available for CANB.
Leadership: Marco Alfonsi
CEO
Marco Alfonsi has a robust background in the healthcare and consumer packaged goods sectors. He has held various leadership roles that emphasize operational efficiency and market expansion. His educational credentials and industry experience position him well to lead Can B Corp. through its growth phases in the competitive CBD market.
Track Record: Under Marco Alfonsi's leadership, Can B Corp. has successfully rebranded from Canbiola Inc. to Can B Corp., reflecting its broader product range. His strategic focus on health and wellness has guided the company in navigating market challenges and leveraging growth opportunities.
CANB OTC Market Information
The OTC Other tier includes companies that do not meet the financial or regulatory requirements for higher tiers like NYSE or NASDAQ. These companies may have lower trading volumes and higher volatility, which can impact investor liquidity and market perception.
- OTC Tier: OTC Other
- Limited financial disclosures compared to companies listed on major exchanges.
- Higher volatility and risk of price manipulation in the OTC market.
- Potential challenges in raising capital due to lower visibility.
- Regulatory scrutiny that may impact operations and product offerings.
- Review the company's financial statements and operational performance.
- Verify the legitimacy of the company's product claims and certifications.
- Assess the competitive landscape and market positioning.
- Monitor regulatory developments affecting the CBD industry.
- Evaluate the company's growth strategy and market expansion plans.
- Established brand names with a history of product offerings.
- Partnerships with healthcare professionals enhancing credibility.
- Transparency in product sourcing and manufacturing processes.
Common Questions About CANB (Healthcare)
What happened to Can B Corp. (CANB) stock?
Can B Corp. (CANB) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
Can I still buy CANB shares?
No. CANB stopped trading on public markets in October 2025, so the shares are not available through a broker. Anything you see quoted for CANB elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CANB stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Can B Corp.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Can B Corp. do?
Can B Corp. specializes in the development and sale of a wide range of CBD products, including oils, topical creams, and lifestyle items. The company operates primarily in the U.S. market and markets its products under various brand names such as Canbiola and Nu Wellness. Their offerings cater to health-conscious consumers seeking natural wellness solutions.
What are the main risks for CANB?
Can B Corp. faces several risks, including regulatory uncertainties that could affect product availability, intense competition from both established and emerging companies in the CBD market, and market volatility associated with trading on the OTC market. Additionally, changing consumer preferences may impact demand for their products, necessitating continuous adaptation and innovation.
How does Can B Corp. navigate regulatory approval processes?
Can B Corp. must comply with various federal and state regulations governing the sale of CBD products. This involves ensuring that their products meet safety and labeling standards set by regulatory bodies. The company actively monitors changes in legislation and adapts its product offerings to remain compliant, which is crucial for maintaining market access and consumer trust.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company operates in a highly regulated industry, and its financial performance may be influenced by external market conditions.